These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 17256784

  • 21. A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection.
    do O NT, Eurich D, Schmitz P, Schmeding M, Heidenhain C, Bahra M, Trautwein C, Neuhaus P, Neumann UP, Wasmuth HE.
    Liver Transpl; 2012 Mar; 18(3):298-304. PubMed ID: 22139994
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection.
    Kuo A, Tan V, Lan B, Khalili M, Feng S, Roberts JP, Terrault NA.
    Liver Transpl; 2008 Oct; 14(10):1491-7. PubMed ID: 18825708
    [Abstract] [Full Text] [Related]

  • 24. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation.
    Machicao VI, Krishna M, Bonatti H, Aqel BA, Nguyen JH, Weigand SD, Rosser BG, Hughes C, Dickson RC.
    Liver Transpl; 2004 May; 10(5):599-606. PubMed ID: 15108251
    [Abstract] [Full Text] [Related]

  • 25. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation.
    McTaggart RA, Terrault NA, Vardanian AJ, Bostrom A, Feng S.
    Liver Transpl; 2004 Aug; 10(8):975-85. PubMed ID: 15390322
    [Abstract] [Full Text] [Related]

  • 26. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients.
    Schmeding M, Neumann UP, Puhl G, Bahra M, Neuhaus R, Neuhaus P.
    Liver Transpl; 2007 May; 13(5):687-92. PubMed ID: 17457911
    [Abstract] [Full Text] [Related]

  • 27. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis.
    Samonakis DN, Cholongitas E, Thalheimer U, Kalambokis G, Quaglia A, Triantos CK, Mela M, Manousou P, Senzolo M, Dhillon AP, Patch D, Burroughs AK.
    Liver Transpl; 2007 Sep; 13(9):1305-11. PubMed ID: 17763383
    [Abstract] [Full Text] [Related]

  • 28. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients.
    Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, Brooks BK, Levy MF, Gonwa TA, Klintmalm GB.
    Liver Transpl; 2000 Sep; 6(5):553-61. PubMed ID: 10980053
    [Abstract] [Full Text] [Related]

  • 29. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.
    Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, Radke C, Neuhaus P.
    J Hepatol; 2004 Nov; 41(5):830-6. PubMed ID: 15519657
    [Abstract] [Full Text] [Related]

  • 30. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
    Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, Paya CV, Charlton MR.
    Liver Transpl; 2002 Apr; 8(4):362-9. PubMed ID: 11965581
    [Abstract] [Full Text] [Related]

  • 31. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C.
    Ciccorossi P, Maina AM, Oliveri F, Petruccelli S, Leandro G, Colombatto P, Moriconi F, Mosca F, Filipponi F, Bonino F, Brunetto MR.
    Liver Int; 2007 Jun; 27(5):612-9. PubMed ID: 17498245
    [Abstract] [Full Text] [Related]

  • 32. Outcomes of acute rejection after interferon therapy in liver transplant recipients.
    Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H, Goldstein LI, Lassman CR, Busuttil RW.
    Liver Transpl; 2004 Jul; 10(7):859-67. PubMed ID: 15237369
    [Abstract] [Full Text] [Related]

  • 33. Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome.
    Katz LH, Mor E, Brown M, Bar-Nathan N, Shaharabani E, Sulkes J, Pappo O, Tur-Kaspa R, Ben-Ari Z.
    Clin Transplant; 2006 Jul; 20(4):465-70. PubMed ID: 16842523
    [Abstract] [Full Text] [Related]

  • 34. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4.
    Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ.
    Liver Transpl; 2003 Aug; 9(8):796-804. PubMed ID: 12884191
    [Abstract] [Full Text] [Related]

  • 35. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
    Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS.
    Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
    [Abstract] [Full Text] [Related]

  • 36. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.
    Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, Piscaglia F, Tamè M, Pinna AD.
    Liver Transpl; 2009 Jul; 15(7):782-9. PubMed ID: 19562715
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation.
    Guillaud O, Gurram KC, Puglia M, Lilly L, Adeyi O, Renner EL, Selzner N.
    Transplant Proc; 2013 Jul; 45(6):2331-6. PubMed ID: 23953545
    [Abstract] [Full Text] [Related]

  • 38. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, Minola E, Guido M, Boccagni P, De Feo TM, Torelli R, Cardillo M, Scalamogna M, Poli F.
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [Abstract] [Full Text] [Related]

  • 39. Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C.
    Cisneros L, Londoño MC, Blasco C, Bataller R, Miquel R, Bruguera M, Ginès P, Rimola A.
    Liver Transpl; 2007 Jul; 13(7):1017-27. PubMed ID: 17600343
    [Abstract] [Full Text] [Related]

  • 40. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study.
    Khettry U, Anand N, Faul PN, Lewis WD, Pomfret EA, Pomposelli J, Jenkins RL, Gordon FD.
    Liver Transpl; 2003 Jan; 9(1):87-96. PubMed ID: 12514778
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.